{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"138-863-549-359-570","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"138-863-549-359-570","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11797,"type":"PATENT","title":"Queen's University at Kingston Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5666,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8427,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: queen* AND univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1261
Search Applicants and Owners separately: queen* AND univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1261
wherein the nanoparticles comprise gold\n
and wherein the anti-nucleolin agent is AS1411 (SEQ ID NO: 10)."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The composition of claim 1, further comprising a cyanine dye."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The composition of claim 1, wherein the nanoparticles have an average diameter of 1 to 50 nm."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The composition of claim 1, wherein the nanoparticles have an average diameter of 1 to 20 nm."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition, comprising the composition of claim 1 and a pharmaceutically acceptable carrier."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating cancer, comprising administering an effective amount of the pharmaceutical composition of claim 5, to a patient in need thereof."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein the cancer is selected from the group consisting of melanoma, lymphoma, plasmocytoma, sarcoma, glioma, thymoma, leukemia, breast cancer, prostate cancer, colon cancer, liver cancer, esophageal cancer, brain cancer, lung cancer, ovary cancer, endometrial cancer, bladder cancer, kidney cancer, cervical cancer and hepatoma."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, colon cancer and lung cancer."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, further comprising administering a second cancer treatment selected from the group consisting of vinorelbine, mytomycin, camptothecin, cyclyphosphamide, methotrexate, tamoxifen citrate, 5-fluorouracil, irinotecan, doxorubicin, flutamide, paclitaxel, docetaxel, vinblastine, imatinib mesylate, anthracycline, letrozole, arsenic trioxide, anastrozole, triptorelin pamoate, ozogamicin, irinotecan hydrochloride, BCG live, leuprolide acetate implant, bexarotene, exemestane, topotecan hydrochloride, gemcitabine HCL, daunorubicin hydrochloride, toremifene citrate, carboplatin, cisplatin, oxaliplatin and any other platinum-containing oncology drug, trastuzumab, lapatinib, gefitinb, cetuximab, panitumumab, temsirolimus, everolimus, vandetanib, vemurafenib, crizotinib, vorinostat, bevacizumab, radiation therapy, hyperthermia, gene therapy and photodynamic therapy."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition, comprising the composition of claim 2 and a pharmaceutically acceptable carrier."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition, comprising the composition of claim 3 and a pharmaceutically acceptable carrier."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition, comprising the composition of claim 4 and a pharmaceutically acceptable carrier."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating cancer, comprising administering an effective amount of the pharmaceutical composition of claim 10, to a patient in need thereof."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating cancer, comprising administering an effective amount of the pharmaceutical composition of claim 11, to a patient in need thereof."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating cancer, comprising administering an effective amount of the pharmaceutical composition of claim 12, to a patient in need thereof."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the cancer is selected from the group consisting of melanoma, lymphoma, plasmocytoma, sarcoma, glioma, thymoma, leukemia, breast cancer, prostate cancer, colon cancer, liver cancer, esophageal cancer, brain cancer, lung cancer, ovary cancer, endometrial cancer, bladder cancer, kidney cancer, cervical cancer and hepatoma."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 16, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, colon cancer and lung cancer."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, further comprising administering a second cancer treatment selected from the group consisting of vinorelbine, mytomycin, camptothecin, cyclyphosphamide, methotrexate, tamoxifen citrate, 5-fluorouracil, irinotecan, doxorubicin, flutamide, paclitaxel, docetaxel, vinblastine, imatinib mesylate, anthracycline, letrozole, arsenic trioxide, anastrozole, triptorelin pamoate, ozogamicin, irinotecan hydrochloride, BCG live, leuprolide acetate implant, bexarotene, exemestane, topotecan hydrochloride, gemcitabine HCL, daunorubicin hydrochloride, toremifene citrate, carboplatin, cisplatin, oxaliplatin and any other platinum-containing oncology drug, trastuzumab, lapatinib, gefitinb, cetuximab, panitumumab, temsirolimus, everolimus, vandetanib, vemurafenib, crizotinib, vorinostat, bevacizumab, radiation therapy, hyperthermia, gene therapy and photodynamic therapy."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, colon cancer and lung cancer."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14, further comprising administering a second cancer treatment selected from the group consisting of vinorelbine, mytomycin, camptothecin, cyclyphosphamide, methotrexate, tamoxifen citrate, 5-fluorouracil, irinotecan, doxorubicin, flutamide, paclitaxel, docetaxel, vinblastine, imatinib mesylate, anthracycline, letrozole, arsenic trioxide, anastrozole, triptorelin pamoate, ozogamicin, irinotecan hydrochloride, BCG live, leuprolide acetate implant, bexarotene, exemestane, topotecan hydrochloride, gemcitabine HCL, daunorubicin hydrochloride, toremifene citrate, carboplatin, cisplatin, oxaliplatin and any other platinum-containing oncology drug, trastuzumab, lapatinib, gefitinb, cetuximab, panitumumab, temsirolimus, everolimus, vandetanib, vemurafenib, crizotinib, vorinostat, bevacizumab, radiation therapy, hyperthermia, gene therapy and photodynamic therapy."],"number":20,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}